Welcome to our dedicated page for Artelo Biosciences SEC filings (Ticker: ARTL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Wondering where Artelo Biosciences discloses the cash it burns on clinical trials or how often executives buy shares? You can stop hunting through EDGAR. This page gathers every Artelo Biosciences SEC filing鈥攆rom the detailed annual report 10-K to fast 8-K material event notices鈥攕econds after they post.
Start with the Artelo Biosciences quarterly earnings report 10-Q filing to see R&D spend and runway projections. Need drug-trial milestones or licensing updates? Our AI extracts them from each 8-K, then explains why they matter for a small-cap biotech. If you鈥檙e tracking leadership moves, real-time alerts flag Artelo Biosciences insider trading Form 4 transactions, letting you compare option exercises against upcoming data releases.
Stock Titan鈥檚 platform turns dense documents into plain language:
- AI-powered highlights that answer 鈥渦nderstanding Artelo Biosciences SEC documents with AI鈥�.
- Side-by-side trends across every Artelo Biosciences annual report 10-K simplified since IPO.
- Instant Form 4 dashboards for 鈥淎rtelo Biosciences executive stock transactions Form 4鈥�.
- Key tables pulled from the proxy statement so you can evaluate 鈥淎rtelo Biosciences proxy statement executive compensation鈥�.
Embrace Change Acquisition Corp (EMCG) will hold an EGM on 11 Aug 2025 to vote on three items: (1) a charter amendment extending the deadline to close a business combination by 12 months to 12 Aug 2026; (2) a parallel amendment to the trust agreement; and (3) authority to adjourn if needed.
The SPAC has already paid for three one-month extensions (total $225k) but skipped eight required payments, creating $675k in arrears. Passage of the proposals would allow the board to extend without depositing further funds. Failure triggers mandatory redemption and liquidation within five business days.
Shareholders may redeem at approximately $12.08 per share versus the 25 Jul 2025 Nasdaq price of $12.15; the trust currently holds $26.9 m. The sponsor and insiders control 49.2 % of outstanding shares and cannot redeem. The extension amendment needs a two-thirds vote; the trust amendment needs a simple majority of votes cast.
Entrada Therapeutics, Inc. (TRDA) 鈥� Form 4 Insider Transaction
On 07/09/2025, funds affiliated with venture-capital firm 5AM Ventures, a 10% beneficial owner of Entrada, reported open-market sales of the company鈥檚 common stock:
- 5AM Ventures V, L.P. sold 20,065 shares at $7.502 per share (鈮� $150 k) and now holds 3,163,066 shares directly.
- 5AM Opportunities I, L.P. sold 6,935 shares at the same price (鈮� $52 k) and now holds 1,093,313 shares indirectly.
No derivative securities were involved, and there were no purchases disclosed. The reporting group鈥攃omprising 5AM Partners entities and managing members Dr. Scott M. Rocklage and Andrew J. Schwab鈥攃ontinues to own more than four million shares in aggregate but trimmed its position by roughly 27,000 shares in a single session.
The transactions represent a relatively small reduction of the group鈥檚 overall stake yet may signal routine portfolio rebalancing or liquidity management by a long-term holder.
Artelo Biosciences, Inc. (ARTL) filed an 8-K on 11 July 2025 announcing two key items:
- Reverse stock split: A previously disclosed 1-for-6 reverse split became effective on 13 June 2025. Outstanding shares shrank from 3.28 million to roughly 546,667. Authorized common shares fell from 50 million to 8.33 million and authorized preferred shares from 416,667 to 69,444. Par value remains $0.001.
- Preliminary mid-year financial update (unaudited): Management estimates cash, cash equivalents and short-term investments of $2.1 million as of 30 June 2025. Working capital is expected to range between $(1.2) million and $(1.5) million.
The company reiterates a substantial-doubt going-concern warning first disclosed in its March 31 2025 10-Q (Note 1). MaloneBailey, LLP has not reviewed or audited the new estimates.
To reflect the share reclassification, Artelo is republishing audited FY 2023-2024 financial statements (Exhibit 99.1) and unaudited Q1 2025 financials (Exhibit 99.2).
While the reverse split may assist with Nasdaq listing compliance, the limited liquidity and negative working capital underline the firm鈥檚 challenged financial position.
Artelo Biosciences, Inc. (ARTL) filed a new Form D on 9 Jul 2025 that covers a $1.425 million private placement conducted under Regulation D Rule 506(b).
- Total offering & amount sold: $1,425,000; amount remaining: $0, indicating the raise is already fully subscribed.
- Date of first sale: 26 Jun 2025; the company does not expect the offering to last longer than one year.
- Securities offered: common equity, options/warrants, and the shares issuable upon exercise of those instruments.
- Investors: 8 accredited investors participated; no non-accredited investors and no minimum investment requirement were specified.
- Costs: No sales commissions or finders鈥� fees were paid, and none of the proceeds are earmarked for payments to directors, officers, or promoters.
- Industry & issuer details: Nevada-incorporated biotechnology company; revenue size not disclosed.
The notice signals completion of a small but cost-efficient capital raise that adds liquidity while increasing potential share count through equity-linked securities.
National Rural Utilities Cooperative Finance Corporation (NRUC) has filed a preliminary pricing supplement for new subordinated deferrable interest notes (CUSIP 63743LAY9).
- Coupon: 5.750% fixed, paid semi-annually; first payment on 01/15/2026 ($28.43 per $1,000).
- Maturity: 07/15/2055 (30-year tenor).
- Redemption: Callable at the issuer鈥檚 option at par plus accrued interest on or after 07/15/2030 (Par Call Period).
- Offering terms: Sold at 100% of face value with a 3.150% selling concession; minimum denomination $1,000; book-entry through DTC; trade date 07/14/2025, settlement 07/17/2025.
- Investor protections: Survivor鈥檚 option permits heirs to put the notes back to the issuer at par.
- Ranking: Subordinated notes, junior to senior debt and senior to equity.
Net proceeds (undisclosed amount) will increase NRUC鈥檚 long-term, fixed-rate debt, locking in funding costs but adding interest expense. No financial statements or aggregate issuance size are included in this filing.
Artelo Biosciences (Nasdaq: ARTL) entered into a securities purchase agreement on 24-Jun-2025 for a private placement of 136,843 common shares at $5.82 plus warrants covering 783,249 shares.
Gross proceeds: $1.425 million today, up to $6.403 million if all warrants are exercised. Instruments include pre-funded warrants (93,180 shares, $0.001 strike) and 5-year warrants at $5.82 (460,046 shares) and $10.00 (230,023 shares), all subject to 4.99%-9.99% ownership caps.
- Unit price: $6.195 per share and three warrants.
- Closing expected 26-Jun-2025.
- Company will file resale registration within 15 days.
- $250,000 of net proceeds earmarked to purchase SOL cryptocurrency; remainder for working capital.
The sale is exempt under Rule 506 of Regulation D; investors are accredited.
FAQ
What is the current stock price of Artelo Biosciences (ARTL)?
What is the market cap of Artelo Biosciences (ARTL)?
What is the primary focus of Artelo Biosciences?
What types of therapies is Artelo developing?
How does Artelo Biosciences differentiate itself in the biopharmaceutical industry?
Where is Artelo Biosciences headquartered?
What is the significance of the company鈥檚 proprietary cocrystal technology?
What conditions are targeted by Artelo鈥檚 FABP inhibitors?
How does Artelo Biosciences support its research and development efforts?
Is Artelo focused on addressing unmet medical needs?
